According to our latest study on “Radiopharmaceuticals Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Type, Product Type, Application, and End User,” the market is projected to reach US$ 13,818.17 million by 2028 from US$ 7,550.74 million in 2021; it is expected to grow at a CAGR of 9.0% from 2021 to 2028. The report highlights the key factors driving the market growth and prominent players with their developments in the market.

The COVID-19 pandemic has negatively impacted the US radiopharmaceutical market. As per the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the outbreak had changed the policies for radiopharmaceutical preparations in nuclear medicine (NM) departments by negatively impacting the regular operation of radiopharmacy labs. The COVID-19 crisis has a potential economic impact on most of the sectors, including the oncology procedures. The pandemic has hindered cancer diagnosis and surgeries and is likely to negatively impact the market.

Get Exclusive Sample Copy of This Report @ https://www.theinsightpartners.com/sample/TIPRE00003751/

Based on product type, the radiopharmaceuticals market is segmented into Technetium-99m, Thallium-201, Gallium-67, Iodine-131, Copper-64, and other. The Technetium-99m segment is estimated to hold the largest share in the market during the forecast period. The market growth for this segment is attributed to its wide range of application in single photon emission computed tomography (SPECT). For instance, Neurolite (Technetium-99m bicisate) manufactured by Lantheus Medical Imaging is used as an adjunct in the localization of stroke in patients in SPECT imaging.

Cardinal Health, GE Healthcare, Curium, Lantheus Medical Imaging, Bayer AG, Bracco Imaging, Eczacýbaþý-Monrol Nuclear Products, Nordion, Advanced Accelerator Applications, and NTP Radioisotopes are among leading companies operating in the global radiopharmaceuticals market.

The radiopharmaceuticals market is segmented on the basis of type, product type, application, and end user. Based on type, the market is bifurcated into diagnostic nuclear medicine and therapeutic nuclear medicine. The diagnostic nuclear medicine is further bifurcated into SPECT (Single-Photon Emission Computed Tomography) applications and PET (Positron Emission Tomography) applications. The therapeutic nuclear medicine is further segmented into alpha emitters, beta emitters, and brachytherapy isotopes. Based on product type, the market is segmented into Technetium-99m, Thallium-201, Gallium-67, Iodine-131, Copper-64, and other. Based on application, the market is segmented into oncology, cardiology, neurology, and others. By end user, the market is segmented into hospitals, imaging centers, academic and research centers, and others.

The report segments radiopharmaceuticals market as follows:

By Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • France
  • Germany
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific (APAC)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • Rest of APAC
• Middle East and Africa (MEA)
  • Saudi Arabia
  • UAE
  • South Africa
  • Rest of MEA
• South and Central America (SCAM)
  • Brazil
  • Argentina
  • Rest of SCAM

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:
If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Ankit Mathur
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876